A Pivotal Phase 3 Study of OCU 310 in Patients with Chronic Dry Eye Disease
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2018
At a glance
- Drugs Brimonidine/loteprednol-etabonate (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Ocugen
- 01 Oct 2018 According to an Ocugen media release, topline data are expected in in the second half of 2019.
- 01 Oct 2018 Status changed from planning to recruiting, according to an Ocugen media release.
- 22 Mar 2018 New trial record